Skip to main content

Table 2 The rates of treatment response in different BLPD subgroups

From: Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China

Subgroup (NO.)

CR (n, %)

P value

ORR (n, %)

P value

CLL (151)

 

<0.001

 

<0.001

 R-group (44)

24 (54.5 %)

 

40 (90.9 %)

 

 Non-R-group (107)

14 (13.1 %)

 

48 (44.9 %)

 

FL (41)

 

0.044

 

0.008

 R-group (28)

20 (71.4 %)

 

28 (100 %)

 

 Non-R-group (13)

5 (38.5 %)

 

10 (76.9 %)

 

Other BLPD (142)

 

<0.001

 

<0.001

 R-group (56)

37 (66.1 %)

 

51 (91.1 %)

 

 Non-R-group (86)

14 (16.3 %)

 

52 (60.5 %)

 
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us